(Q46699478)

English

A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

0 references

0 references

hospital-acquired pneumonia

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

J L Kuti

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

M Dowzicky

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

D P Nicolau

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

publication date

1 February 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

Journal of Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

20

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

69-76

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

The glycylcyclines: a comparative review with the tetracyclines

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Intermittent bolus dosing of ceftazidime in critically ill patients.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Making the most of surveillance studies: summary of the OPTAMA Program

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.1.69

21 January 2018

Identifiers

10.1179/JOC.2008.20.1.69

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18343747

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46699478&oldid=2144208904"